Prevalence and characteristics of patients with seronegative myasthenia gravis [0.03%]
自身抗体阴性的重症肌无力患者的发生率和特点分析
Rebecca Kjær Andersen,Peter Ankjær,Kasper Holst Axelsen et al.
Rebecca Kjær Andersen et al.
Myasthenia gravis is an autoimmune disorder characterized by antibodies targeting the neuromuscular junction, causing fatigue of skeletal muscle. Natural history and epidemiological studies report that around 10% of patients diagnosed with ...
Streamlining Alzheimer's disease diagnosis: real-world validation of two-cut-off diagnostic models based on plasma p-tau/Aβ42 ratios [0.03%]
基于血浆p- tau / Aβ42 比率的两种截止值诊断模型的真实世界验证以简化阿尔茨海默病的诊断
Martina Poli,Chiara Giuseppina Bonomi,Martina Gaia Di Donna et al.
Martina Poli et al.
Introduction: Anti-amyloid monoclonal antibodies have increased the need for scalable, minimally invasive biomarkers for Alzheimer's disease (AD). In this single-center cohort study, we evaluated plasma biomarkers perform...
The practice effect of smartphone-derived cognitive processing speed assessments as a proxy of cognitive functioning in multiple sclerosis [0.03%]
基于智能手机的认知处理速度评估作为多发性硬化症认知功能替代指标的实践效应
Daan J de Jong,Pam C G Molenaar,Vera Verhoef et al.
Daan J de Jong et al.
Background: In multiple sclerosis (MS), symbol digit modalities test (SDMT) scores are often influenced by practice effects. We evaluated the SDMT practice effect as a proxy of cognitive performance by relating it to dise...
Refining neuropsychological assessment strategies in multiple sclerosis: insights from long-term cognitive trajectories [0.03%]
从长期认知轨迹中洞察多发性硬化症神经心理评估策略的改进
Gianpaolo Maggi,Manuela Altieri,Alessandro d&#x;Ambrosio et al.
Gianpaolo Maggi et al.
Objective: Cognitive evolution in people with multiple sclerosis (pwMS) may follow different trajectories. This study investigated long-term cognitive evolution in pwMS while controlling for methodological factors and psy...
A new era in neuropharmacology: assessing the efficacy and safety of novel anti-amyloid and non-amyloid drug targets for Alzheimer's disease [0.03%]
神经药理学的新时代：评估针对阿尔茨海默病新型抗淀粉样蛋白和非淀粉样蛋白药物靶点的疗效和安全性
Mohamed M Hafez,Haidy A Abbas,Nabil A Shoman et al.
Mohamed M Hafez et al.
Background: Alzheimer disease (AD) is the most common cause of dementia in the world with the prevalence expected to increase threefold to 152.8 million people by 2050. The current medications provide a short-term amelior...
Prospective gait analysis in patients from the French registry of glycogen storage disease type III: implications for clinical trials [0.03%]
法国III型糖原贮积病注册患者前瞻性步态分析在临床试验中的意义
Jean-Yves Hogrel,Frédéric Fer,Isabelle Ledoux et al.
Jean-Yves Hogrel et al.
Background and objectives: Glycogen storage disease type III (GSD-III) is a genetic metabolic disorder affecting liver and muscle, frequently leading to walking difficulties in adults. This study aimed to quantify walking...
"Getting to diagnosis was an absolute nightmare": survey insights about the lived experience of spinal CSF leak in Australia and Aotearoa New Zealand [0.03%]
“确诊的过程是一场绝对的噩梦”: 关于澳大利亚和奥塔哥新西兰脊柱脑脊液漏患者生活经历的调查见解
Lachlan S W Knight,Rachel L Smith,Alexis Ceecee Britten-Jones et al.
Lachlan S W Knight et al.
Background: Spinal cerebrospinal fluid (CSF) leak is a disabling and often misdiagnosed condition characterised by CSF hypovolemia. Associated neurological symptoms are diverse and often leave individuals bed-bound due to...
Factors influencing accelerated progression in behavioral variant frontotemporal dementia [0.03%]
影响行为变异型额颞叶痴呆加速进展的因素
Molly Split,Zachary J Kunicki,Daliah Ross et al.
Molly Split et al.
Introduction: This study aimed to identify neuropsychiatric, motor, and cognitive features associated with accelerated disease progression in behavioral variant frontotemporal dementia (bvFTD). ...
Outcome associations of CSF total tau in suspected non-Alzheimer pathophysiology [0.03%]
疑似非阿尔茨海默病病理生理过程患者脑脊液tau蛋白与临床特征的关系
Nils Briel,Marc Borsi,Simon J Schreiner et al.
Nils Briel et al.
Introduction: Cognitively impaired patients with negative biomarkers of amyloidosis but with neurochemical evidence of Tau pathophysiology or neurodegeneration or both are classified as "suspected non-Alzheimer pathophysi...
Multicenter Study
Journal of neurology. 2026 Apr 30;273(5):296. DOI:10.1007/s00415-026-13841-x 2026
Identifying diagnostic biomarkers in functional motor disorders through multimodal behavioral, neurophysiological, and imaging assessment using explainable machine learning [0.03%]
基于可解释机器学习的多模态行为、神经生理和影像评估在功能性运动障碍诊断生物标志物识别中的应用
Marialuisa Gandolfi,Angela Sandri,Michela Russo et al.
Marialuisa Gandolfi et al.
Background: Functional motor disorders (FMDs) represent a frequent and disabling neurological condition. The lack of reliable diagnostic biomarkers and their heterogeneity might affect diagnosis. We identified multimodal ...
Multicenter Study
Journal of neurology. 2026 Apr 30;273(5):299. DOI:10.1007/s00415-026-13838-6 2026